COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has shared an update.
Cosmo Pharmaceuticals announced that Endovision Limited has received EU-MDR certification for Cerebro, a real-time AI-powered guide for esophagogastroduodenoscopy (EGD) procedures. This certification marks a significant advancement in endoscopic imaging, enhancing examination quality and treatment outcomes. The Cerebro software, integrated into the Medtronic GI Genius™ system, uses advanced algorithms to improve the quality of upper gastrointestinal tract interventions, complementing existing solutions for the lower tract. This development aligns with Cosmo’s strategy to integrate AI into clinical practice, offering substantial benefits for patient care and positioning the company as a pioneer in AI-driven endoscopy.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on revolutionizing healthcare through innovative products in Healthtech/AI, Dermatology, Gastroenterology, and contract manufacturing and development. Founded in 1997 and headquartered in Dublin, Ireland, with branches in the USA and Italy, Cosmo collaborates with global partners like Medtronic and Sun Pharma to commercialize and distribute its products.
YTD Price Performance: -25.54%
Average Trading Volume: 602
Technical Sentiment Signal: Buy
Current Market Cap: CHF802.3M
For an in-depth examination of COPN stock, go to TipRanks’ Stock Analysis page.